Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

2.4K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.4K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.9K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of a non-invasive oestrous synchronisation protocol on sexual behaviour in Sprague-Dawley rats.

The journal of sexual medicine·2026
Same author

A single S-ketamine injection enhances mTOR signaling in rat skeletal muscle.

Journal of muscle research and cell motility·2026
Same author

In Memoriam: Professor Dan J. Stein (1962-2025) - A Global Pioneer with an African Heart.

The international journal of neuropsychopharmacology·2025
Same author

Agomelatine normalizes region-specific, diurnal mGluR5 dysregulation in a chronic mild stress rat model of depression.

Progress in neuro-psychopharmacology & biological psychiatry·2025
Same author

Neuropsychiatric- and cognitive post-acute sequelae of SARS-CoV-2 infection - evidence from K18-hACE C57BL/6 J mice.

The international journal of neuropsychopharmacology·2025
Same author

A Model-Based Approach to Neuronal Electrical Activity and Spatial Organization Through the Neuronal Actin Cytoskeleton.

Methods and protocols·2025
Same journal

Commentary on: The American Society of Clinical Psychopharmacology task force consensus statement on the deprescribing of stimulant medications in adults with ADHD.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026
Same journal

Corrigendum to "Functioning assessment short test for autism (FAST-A): a tool to evaluate adaptive functioning in autistic adults" [European Neuropsychopharmacology, 112, 112887].

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026
Same journal

Genomic relationship between polyendocrine metabolic ovarian syndrome and bipolar disorder.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026
Same journal

Genetic overlap between depression and C-reactive protein levels: Evidence from a cross-trait analysis.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026
Same journal

Variability in AI-generated psychedelic definitions across major chatbots.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026
Same journal

In-patient treatment and structural dysconnectivity in major depression - A longitudinal connectome study.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026
See all related articles

Related Experiment Video

Updated: Apr 18, 2026

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

12.8K

Electroconvulsive shocks decrease α2-adrenoceptor binding in the Flinders rat model of depression.

Thea P Lillethorup1, Peter Iversen2, Jesper Fontain1

  • 1Department of Nuclear Medicine and PET Center, Aarhus University Hospital, Denmark; Center of Functionally Integrative Neuroscience/MINDlab, Aarhus University, Denmark.

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|January 22, 2015
PubMed
Summary
This summary is machine-generated.

Electroconvulsive therapy (ECT) effectively treats severe depression by potentially increasing noradrenergic neurotransmission. This study found electroconvulsive shock (ECS) decreased alpha2-adrenoceptor binding in specific brain regions, suggesting a mechanism for ECT

Keywords:
AutoradiographyElectroconvulsive therapyFlinders resistant line ratsFlinders sensitive line ratsα(2)-Adrenoceptors

More Related Videos

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

30.0K
The Optical Fractionator Technique to Estimate Cell Numbers in a Rat Model of Electroconvulsive Therapy
07:55

The Optical Fractionator Technique to Estimate Cell Numbers in a Rat Model of Electroconvulsive Therapy

Published on: July 9, 2017

12.2K

Related Experiment Videos

Last Updated: Apr 18, 2026

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

12.8K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

30.0K
The Optical Fractionator Technique to Estimate Cell Numbers in a Rat Model of Electroconvulsive Therapy
07:55

The Optical Fractionator Technique to Estimate Cell Numbers in a Rat Model of Electroconvulsive Therapy

Published on: July 9, 2017

12.2K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Electroconvulsive therapy (ECT) is a highly effective treatment for severe depression, yet its precise therapeutic mechanisms remain unclear.
  • Previous research indicated altered alpha2-adrenoceptor binding in Flinders sensitive line (FSL) and Flinders resistant line (FRL) rats compared to Sprague-Dawley (SD) controls.
  • The noradrenergic system and alpha2-adrenoceptors are implicated in depression and antidepressant treatment efficacy.

Purpose of the Study:

  • To investigate the hypothesis that ECT's antidepressant effects involve increased noradrenergic neurotransmission, leading to reduced alpha2-adrenoceptor binding.
  • To examine the impact of electroconvulsive shock (ECS), an animal model of ECT, on alpha2-adrenoceptor densities in specific brain regions of FSL, FRL, and SD rats.
  • To elucidate the role of the noradrenergic system and alpha2-adrenoceptors in the therapeutic mechanism of ECT.

Main Methods:

  • Female FSL, FRL, and SD rats were subjected to either ECS or sham stimulation for 10 days.
  • Brain tissues were sectioned, and quantitative autoradiography was employed to measure alpha2-adrenoceptor densities.
  • The alpha2-adrenoceptor antagonist, [(3)H]RX 821002, was used to quantify receptor binding in the hippocampus, thalamus, hypothalamus, amygdala, frontal cortex, insular cortex, and perirhinal cortex.

Main Results:

  • ECS treatment resulted in decreased alpha2-adrenoceptor binding in cortical regions of FSL rats.
  • In FRL rats, ECS reduced alpha2-adrenoceptor binding in cortical and amygdaloid regions.
  • Normal SD control rats did not exhibit significant changes in alpha2-adrenoceptor binding following ECS treatment.

Conclusions:

  • The findings suggest that the therapeutic effects of ECS may be mediated by a reduction in alpha2-adrenoceptor binding, potentially due to increased noradrenaline release.
  • These results underscore the significance of the noradrenergic system and alpha2-adrenoceptors in the pathophysiology of depression.
  • The study reinforces the role of alpha2-adrenoceptor modulation as a key mechanism in antidepressant treatments like ECT.